Are You Speaking the Same Language When Discussing Biomarkers With Your Patients?
Oncology Nurses: Have You Read a Good Book Lately?
“In hindsight, I understood the science behind why the trials were being conducted, but probably did not appreciate their history.”
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
